Discussion about this post

User's avatar
Dr Andrew Bamji's avatar

It was suggested a long way back that IL-1-beta (as well as IL-6) were responsible at least in part for the effects of SARS-CoV-2 induced cytokine storm, thus prompting the use of biologics that suppress them (anakinra and tocilizumab respectively). If spike protein "vaccines" are demonstrably showing increased interleukin production then blocking this would be appropriate - but it begs the question of whether one should be using the vaccines at all.

I have previously drawn a parallel with the introduction of TNF-alpha blockade for inflammatory joint disease. There was a theoretical risk of oncogenesis - TNF is Tumor Necrosis Factor. In the UK a register was established with the aim of assessing that risk and the register (BSR Biologics register) has now been going since 2001, with many useful spin-off research publications. As it happens, over this period there has not been any evidence of oncogenesis but without the Register we would probably never have known. I believe the risks of the Covid "vaccines" demand the establishment of a similar long-term surveillance program if they continue to be employed. I am not aware of any attempts anywhere to create a register that would enable this.

Expand full comment
rjt's avatar

The experiments with PAMPs at T4 and T5 are interesting with reduced viral reactivity. As well as permitting more sepsis, the result should be more frequent viral infections, which anecdotally we see in our repeatedly vaxxed acquaintances (and our friends, too!)

This appears to be a positive feedback feature of the SARS-CoV-2 spike protein, enhanced by shedding properties of the injection. It would be interesting to study people from highly mRNA vaxxed populations (Israel or Qatar for instance) versus groups from adenovirus injected populations (China or Russia), looking at macrophages and measuring IL-1Beta.

Expand full comment
19 more comments...

No posts